Skip to main content
Erschienen in: Current Urology Reports 3/2016

01.03.2016 | Prostate Cancer (A Kibel, Section Editor)

Grading of Prostate Cancer: Past, Present, and Future

verfasst von: Andres Matoso, Jonathan I. Epstein

Erschienen in: Current Urology Reports | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

The grading of prostate cancer has undergone significant changes since the adoption of the Gleason grading system in the 1970s. Gleason patterns 1 and 2 are no longer in use and the current Gleason score 6 of 10 is the lowest grade possible. Several specific morphologies that were historically considered Gleason grade 3 are currently assigned a Gleason pattern 4. Consequently, current Gleason score 6 cancers have a better prognosis than historic ones. There is now ample literature that supports that Gleason score 7 includes patients with very different prognosis; those with Gleason score 3 + 4 have a much better prognosis than patients with Gleason score 4 + 3. Within patients with high-grade cancer, it is now also clear that patients with Gleason score 8 have a significantly better prognosis than men with Gleason scores 9–10. Additionally, more recent studies have demonstrated that there is no significant difference in the prognosis of patients with Gleason score 9 or 10, making the distinction between the two pointless. A new contemporary grading system has been proposed that addresses these changes/problems and provides a simpler system with only five grades that reflect more accurately the prognosis of each group. We review the different changes applied to the Gleason scoring system since its conception as well as the studies leading to a new contemporary grading system.
Literatur
1.
Zurück zum Zitat Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58–64.PubMed Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58–64.PubMed
2.
Zurück zum Zitat Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29(9):1228–42.CrossRefPubMed Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29(9):1228–42.CrossRefPubMed
3.
Zurück zum Zitat Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014;15(6):e234–42.PubMedCentralCrossRefPubMed Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014;15(6):e234–42.PubMedCentralCrossRefPubMed
4.••
Zurück zum Zitat Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013;111(5):753–60. This is the first study that proposes a new contemporary prostate cancer grading system based on data from Johns Hopkins Hospital.PubMedCentralCrossRefPubMed Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013;111(5):753–60. This is the first study that proposes a new contemporary prostate cancer grading system based on data from Johns Hopkins Hospital.PubMedCentralCrossRefPubMed
5.••
Zurück zum Zitat Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2015. This is a validation multi-istitutional study that supports the new contemporary prostate cancer grading system proposed by Epstein and colleagues in 2013. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2015. This is a validation multi-istitutional study that supports the new contemporary prostate cancer grading system proposed by Epstein and colleagues in 2013.
6.
Zurück zum Zitat Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966;50(3):125–8.PubMed Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966;50(3):125–8.PubMed
7.
8.
Zurück zum Zitat Mellinger GT, Gleason D, Bailar 3rd J. The histology and prognosis of prostatic cancer. J Urol. 1967;97(2):331–7.PubMed Mellinger GT, Gleason D, Bailar 3rd J. The histology and prognosis of prostatic cancer. J Urol. 1967;97(2):331–7.PubMed
9.
Zurück zum Zitat Bailar 3rd JC, Mellinger GT, Gleason DF. Survival rates of patients with prostatic cancer, tumor stage, and differentiation—preliminary report. Cancer Chemother Rep. 1966;50(3):129–36.PubMed Bailar 3rd JC, Mellinger GT, Gleason DF. Survival rates of patients with prostatic cancer, tumor stage, and differentiation—preliminary report. Cancer Chemother Rep. 1966;50(3):129–36.PubMed
10.
Zurück zum Zitat Latour M, Amin MB, Billis A, Egevad L, Grignon DJ, Humphrey PA, et al. Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology. Am J Surg Pathol. 2008;32(10):1532–9.CrossRefPubMed Latour M, Amin MB, Billis A, Egevad L, Grignon DJ, Humphrey PA, et al. Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology. Am J Surg Pathol. 2008;32(10):1532–9.CrossRefPubMed
11.
Zurück zum Zitat Iczkowski KA, Torkko KC, Kotnis GR, Wilson RS, Huang W, Wheeler TM, et al. Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am J Clin Pathol. 2011;136(1):98–107.PubMedCentralCrossRefPubMed Iczkowski KA, Torkko KC, Kotnis GR, Wilson RS, Huang W, Wheeler TM, et al. Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am J Clin Pathol. 2011;136(1):98–107.PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Sarbay BC, Kir G, Topal CS, Gumus E. Significance of the cribriform pattern in prostatic adenocarcinomas. Pathol Res Pract. 2014;210(9):554–7.CrossRefPubMed Sarbay BC, Kir G, Topal CS, Gumus E. Significance of the cribriform pattern in prostatic adenocarcinomas. Pathol Res Pract. 2014;210(9):554–7.CrossRefPubMed
13.
Zurück zum Zitat Kir G, Sarbay BC, Gumus E, Topal CS. The association of the cribriform pattern with outcome for prostatic adenocarcinomas. Pathol Res Pract. 2014;210(10):640–4.CrossRefPubMed Kir G, Sarbay BC, Gumus E, Topal CS. The association of the cribriform pattern with outcome for prostatic adenocarcinomas. Pathol Res Pract. 2014;210(10):640–4.CrossRefPubMed
14.
Zurück zum Zitat Trudel D, Downes MR, Sykes J, Kron KJ, Trachtenberg J, van der Kwast TH. Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. Eur J Cancer. 2014;50(9):1610–6.CrossRefPubMed Trudel D, Downes MR, Sykes J, Kron KJ, Trachtenberg J, van der Kwast TH. Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. Eur J Cancer. 2014;50(9):1610–6.CrossRefPubMed
15.
Zurück zum Zitat Kweldam CF, Wildhagen MF, Steyerberg EW, Bangma CH, van der Kwast TH, van Leenders GJ. Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod Pathol. 2015;28(3):457–64.CrossRefPubMed Kweldam CF, Wildhagen MF, Steyerberg EW, Bangma CH, van der Kwast TH, van Leenders GJ. Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod Pathol. 2015;28(3):457–64.CrossRefPubMed
16.•
Zurück zum Zitat Epstein JI, Egevad L, Amin MB BD, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2015. This is a summary of the most recent changes to the Gleason grading system. Epstein JI, Egevad L, Amin MB BD, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2015. This is a summary of the most recent changes to the Gleason grading system.
17.
18.
Zurück zum Zitat Lane BR, Magi-Galluzzi C, Reuther AM, Levin HS, Zhou M, Klein EA. Mucinous adenocarcinoma of the prostate does not confer poor prognosis. Urology. 2006;68(4):825–30.CrossRefPubMed Lane BR, Magi-Galluzzi C, Reuther AM, Levin HS, Zhou M, Klein EA. Mucinous adenocarcinoma of the prostate does not confer poor prognosis. Urology. 2006;68(4):825–30.CrossRefPubMed
19.
Zurück zum Zitat Osunkoya AO, Nielsen ME, Epstein JI. Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases. Am J Surg Pathol. 2008;32(3):468–72.CrossRefPubMed Osunkoya AO, Nielsen ME, Epstein JI. Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases. Am J Surg Pathol. 2008;32(3):468–72.CrossRefPubMed
20.
Zurück zum Zitat Kovi J, Jackson MA, Heshmat MY. Ductal spread in prostatic carcinoma. Cancer. 1985;56(7):1566–73.CrossRefPubMed Kovi J, Jackson MA, Heshmat MY. Ductal spread in prostatic carcinoma. Cancer. 1985;56(7):1566–73.CrossRefPubMed
21.
Zurück zum Zitat McNeal JE, Yemoto CE. Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. Am J Surg Pathol. 1996;20(7):802–14.CrossRefPubMed McNeal JE, Yemoto CE. Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. Am J Surg Pathol. 1996;20(7):802–14.CrossRefPubMed
22.
Zurück zum Zitat Guo CC, Epstein JI. Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance. Mod Pathol. 2006;19(12):1528–35.CrossRefPubMed Guo CC, Epstein JI. Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance. Mod Pathol. 2006;19(12):1528–35.CrossRefPubMed
23.
Zurück zum Zitat Robinson BD, Epstein JI. Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. J Urol. 2010;184(4):1328–33.CrossRefPubMed Robinson BD, Epstein JI. Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. J Urol. 2010;184(4):1328–33.CrossRefPubMed
24.
Zurück zum Zitat Zhao T, Liao B, Yao J, Liu J, Huang R, Shen P, et al. Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer? Prostate. 2015;75(3):225–32.CrossRefPubMed Zhao T, Liao B, Yao J, Liu J, Huang R, Shen P, et al. Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer? Prostate. 2015;75(3):225–32.CrossRefPubMed
25.
Zurück zum Zitat Watts K, Li J, Magi-Galluzzi C, Zhou M. Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study. Histopathology. 2013;63(4):574–9.PubMed Watts K, Li J, Magi-Galluzzi C, Zhou M. Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study. Histopathology. 2013;63(4):574–9.PubMed
26.
Zurück zum Zitat Van der Kwast T, Al Daoud N, Collette L, Sykes J, Thoms J, Milosevic M, et al. Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy. Eur J Cancer. 2012;48(9):1318–25.CrossRefPubMed Van der Kwast T, Al Daoud N, Collette L, Sykes J, Thoms J, Milosevic M, et al. Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy. Eur J Cancer. 2012;48(9):1318–25.CrossRefPubMed
27.
Zurück zum Zitat Khani F, Epstein JI. Prostate biopsy specimens with Gleason 3 + 3 = 6 and intraductal carcinoma: radical prostatectomy findings and clinical outcomes. Am J Surg Pathol. 2015. Khani F, Epstein JI. Prostate biopsy specimens with Gleason 3 + 3 = 6 and intraductal carcinoma: radical prostatectomy findings and clinical outcomes. Am J Surg Pathol. 2015.
28.
Zurück zum Zitat Kimura K, Tsuzuki T, Kato M, Saito AM, Sassa N, Ishida R, et al. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate. 2014;74(6):680–7.CrossRefPubMed Kimura K, Tsuzuki T, Kato M, Saito AM, Sassa N, Ishida R, et al. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate. 2014;74(6):680–7.CrossRefPubMed
29.
Zurück zum Zitat Pan CC, Potter SR, Partin AW, Epstein JI. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol. 2000;24(4):563–9.CrossRefPubMed Pan CC, Potter SR, Partin AW, Epstein JI. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol. 2000;24(4):563–9.CrossRefPubMed
30.
Zurück zum Zitat Mosse CA, Magi-Galluzzi C, Tsuzuki T, Epstein JI. The prognostic significance of tertiary Gleason pattern 5 in radical prostatectomy specimens. Am J Surg Pathol. 2004;28(3):394–8.CrossRefPubMed Mosse CA, Magi-Galluzzi C, Tsuzuki T, Epstein JI. The prognostic significance of tertiary Gleason pattern 5 in radical prostatectomy specimens. Am J Surg Pathol. 2004;28(3):394–8.CrossRefPubMed
31.
Zurück zum Zitat Sim HG, Telesca D, Culp SH, Ellis WJ, Lange PH, True LD, et al. Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence. J Urol. 2008;179(5):1775–9.CrossRefPubMed Sim HG, Telesca D, Culp SH, Ellis WJ, Lange PH, True LD, et al. Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence. J Urol. 2008;179(5):1775–9.CrossRefPubMed
32.
Zurück zum Zitat Whittemore DE, Hick EJ, Carter MR, Moul JW, Miranda-Sousa AJ, Sexton WJ. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. J Urol. 2008;179(2):516–22. discussion 22.CrossRefPubMed Whittemore DE, Hick EJ, Carter MR, Moul JW, Miranda-Sousa AJ, Sexton WJ. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. J Urol. 2008;179(2):516–22. discussion 22.CrossRefPubMed
33.
Zurück zum Zitat Lucca I, Shariat SF, Briganti A, Lotan Y, Roehrborn CG, Montorsi F, et al. Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model. Urol Oncol. 2015;33(2), 71 e21-6.CrossRefPubMed Lucca I, Shariat SF, Briganti A, Lotan Y, Roehrborn CG, Montorsi F, et al. Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model. Urol Oncol. 2015;33(2), 71 e21-6.CrossRefPubMed
34.
Zurück zum Zitat Adam M, Hannah A, Budaus L, Steuber T, Salomon G, Michl U, et al. A tertiary Gleason pattern in the prostatectomy specimen and its association with adverse outcome after radical prostatectomy. J Urol. 2014;192(1):97–101.CrossRefPubMed Adam M, Hannah A, Budaus L, Steuber T, Salomon G, Michl U, et al. A tertiary Gleason pattern in the prostatectomy specimen and its association with adverse outcome after radical prostatectomy. J Urol. 2014;192(1):97–101.CrossRefPubMed
35.
Zurück zum Zitat Cheng L, Song SY, Pretlow TG, Abdul-Karim FW, Kung HJ, Dawson DV, et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst. 1998;90(3):233–7.CrossRefPubMed Cheng L, Song SY, Pretlow TG, Abdul-Karim FW, Kung HJ, Dawson DV, et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst. 1998;90(3):233–7.CrossRefPubMed
36.
Zurück zum Zitat Ruijter ET, van de Kaa CA, Schalken JA, Debruyne FM, Ruiter DJ. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol. 1996;180(3):295–9.CrossRefPubMed Ruijter ET, van de Kaa CA, Schalken JA, Debruyne FM, Ruiter DJ. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol. 1996;180(3):295–9.CrossRefPubMed
37.
Zurück zum Zitat Amin A, Partin A, Epstein JI. Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy. J Urol. 2011;186(4):1286–90.CrossRefPubMed Amin A, Partin A, Epstein JI. Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy. J Urol. 2011;186(4):1286–90.CrossRefPubMed
Metadaten
Titel
Grading of Prostate Cancer: Past, Present, and Future
verfasst von
Andres Matoso
Jonathan I. Epstein
Publikationsdatum
01.03.2016
Verlag
Springer US
Erschienen in
Current Urology Reports / Ausgabe 3/2016
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-016-0576-4

Weitere Artikel der Ausgabe 3/2016

Current Urology Reports 3/2016 Zur Ausgabe

Kidney Diseases (G Ciancio, Section Editor)

Rectourethral Fistula Management

Female Urology (K Kobashi, Section Editor)

Underactive Bladder

Minimally Invasive Surgery (T Guzzo, Section Editor)

Contemporary Status of Percutaneous Ablation for the Small Renal Mass

Urosurgery (J Collins, Section Editor)

The Utility of Molecular Imaging in Prostate Cancer

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.